{"doi":"10.3346/jkms.2009.24.5.874","title":"Efficacy and Safety of Cabergoline as First Line Treatment for Invasive Giant Prolactinoma","abstract":null,"journal":"Journal of Korean Medical Science","year":2009,"id":41903,"datarank":2.8590570159171462,"base_score":4.248495242049359,"endowment":4.248495242049359,"self_citation_contribution":0.637274286307404,"citation_network_contribution":2.221782729609742,"self_endowment_contribution":0.637274286307404,"citer_contribution":2.221782729609742,"corpus_percentile":null,"corpus_rank":null,"citation_count":69,"citer_count":41,"citers_with_citation_signal":33,"citers_with_endowment":33,"datacite_reuse_total":25,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":201243,"name":"Sang Ah Lee","orcid":null,"position":1,"is_corresponding":false},{"id":201244,"name":"Ji Youn Chung","orcid":null,"position":2,"is_corresponding":false},{"id":201245,"name":"Eun Hee Koh","orcid":null,"position":3,"is_corresponding":false},{"id":201246,"name":"Young Hyun Cho","orcid":null,"position":4,"is_corresponding":false},{"id":201247,"name":"Jeong Hoon Kim","orcid":null,"position":5,"is_corresponding":false},{"id":201248,"name":"Chang Jin Kim","orcid":null,"position":6,"is_corresponding":false},{"id":201249,"name":"Min-Seon Kim","orcid":null,"position":7,"is_corresponding":false},{"id":201242,"name":"Eun-Hee Cho","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":4.248495242049359,"endowment":4.248495242049359,"datacite_reuse_total":25,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19794986","pmcid":"PMC2752771","openalex_id":"https://openalex.org/W2119530081","authors":[],"funders":[],"total_grants":0,"fwci":0.906,"citation_percentile":0.76647923,"influential_citations":0,"citation_trend":[{"year":2012,"count":3},{"year":2013,"count":6},{"year":2014,"count":5},{"year":2015,"count":4},{"year":2016,"count":2},{"year":2017,"count":1},{"year":2018,"count":8},{"year":2019,"count":3},{"year":2020,"count":2},{"year":2021,"count":2},{"year":2022,"count":30},{"year":2024,"count":1}],"oa_status":"gold","license":"cc-by-nc","oa_locations":[{"url":"http://jkms.org/Synapse/Data/PDFData/0063JKMS/jkms-24-874.pdf","host_type":"journal"},{"url":"https://doi.org/10.3346/jkms.2009.24.5.874","host_type":"GOLD"},{"url":"http://jkms.org/Synapse/Data/PDFData/0063JKMS/jkms-24-874.pdf","host_type":"publisher"},{"url":"https://synapse.koreamed.org/DOIx.php?id=10.3346/jkms.2009.24.5.874","host_type":"publisher"},{"url":"https://synapse.koreamed.org/pdf/10.3346/jkms.2009.24.5.874","host_type":"publisher"},{"url":"https://jkms.org/DOIx.php?id=10.3346/jkms.2009.24.5.874","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/19794986","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2752771","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC2752771","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC2752771?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Pituitary Gland Disorders and Treatments","Growth Hormone and Insulin-like Growth Factors","Adrenal and Paraganglionic Tumors","Medicine","Adult","Antineoplastic Agents","Cabergoline","Ergolines","Humans","Magnetic Resonance Imaging","Male","Middle Aged","Pituitary Neoplasms","Prolactin","Prolactinoma","Retrospective Studies"],"mesh_terms":["Cabergoline","Adult","Antineoplastic Agents","Ergolines","Humans","Magnetic Resonance Imaging","Male","Middle Aged","Pituitary Neoplasms","Prolactin","Retrospective Studies","Prolactinoma"],"keywords":["Cabergoline","Prolactinoma","Medicine","Prolactin","Internal medicine","Urology","Gastroenterology","Endocrinology","Hormone","Male","Tumor Size","Invasive Giant Prolactinoma"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[{"doi":"10.6084/m9.figshare.19556341.v1","title":"Additional file 10 of Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19556341","title":"Additional file 10 of Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19556344.v1","title":"Additional file 11 of Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19556344","title":"Additional file 11 of Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19556347.v1","title":"Additional file 12 of Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19556347","title":"Additional file 12 of Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19556350.v1","title":"Additional file 13 of Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19556350","title":"Additional file 13 of Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19556353.v1","title":"Additional file 14 of Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19556353","title":"Additional file 14 of Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19556356.v1","title":"Additional file 1 of Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19556356","title":"Additional file 1 of Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19556359.v1","title":"Additional file 2 of Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19556359","title":"Additional file 2 of Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19556362.v1","title":"Additional file 3 of Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19556362","title":"Additional file 3 of Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19556365.v1","title":"Additional file 4 of Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19556365","title":"Additional file 4 of Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19556368.v1","title":"Additional file 5 of Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19556368","title":"Additional file 5 of Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19556371.v1","title":"Additional file 6 of Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19556371","title":"Additional file 6 of Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19556374.v1","title":"Additional file 7 of Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19556374","title":"Additional file 7 of Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.19556377.v1","title":"Additional file 8 of Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","publisher":"figshare","resource_type":"JournalArticle"}],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-13T14:03:32.938992Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}